# Sophie Pierrin-Lepinard

> Sophie Pierrin-Lepinard is a seed investor at KREAXI (Paris) backing Health Care and Medical. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [KREAXI](https://shizune.co/investors/profile/rhne-alpes-cration)
- Location: Paris, France
- Total investments: 4
- Last investment: Jun 2025
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/sophie-pierrin-lepinard/44/138/733

Sophie Pierrin-Lepinard is a seed investor at KREAXI in Paris focused on Health Care and Medical. Sophie Pierrin-Lepinard - Managing Director @ KREAXI

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 100% |
| Medical | 2 | 50% |
| Biotechnology | 2 | 50% |
| Medical Device | 2 | 50% |
| Big Data | 1 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 50% |
| Series A | 2 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DESKi | DESKi, “learn” in Breton, is a young and innovative company, combining a strong expertise in both medical imaging and artificial intelligence. DESKi works hand in hand with medical practitioners and researchers to develop automated, accurate, and data-driven image analysis tools for an enhanced patient care. | $6M | Seed | Jun 18, 2025 |  |
| Ciliatech | Ciliatech is a medtech company specialized in ophthalmology, develops a new class of implant to address the increasing need to treat glaucoma durably and with very minimal adverse effects. | $1.9M | Series A | Apr 25, 2023 |  |
| DAMAE Medical | Damae Medical is a Paris, France-based medtech company. It has developed a medical device capable of seeing biological tissues in depth, at a cellular level and in vivo. This innovative optical imaging technology will especially allow dermatologists to evaluate in a precise, efficient and rapid way malignancy of tumors by a simple contact with thesurface of the skin. DAMAE Medical’s mission is to put the great power of bio-photonics at the service of opening new opportunities in medical imaging and diagnosis. | $5.7M | Series A | Feb 03, 2022 |  |
| Lucine | Lucine has the ambition to transform and improve patient’s health. Their main therapeutic area is pain. The product, a digital therapeutic is able to relieve patient’s pain in 5 minutes through active substances allowing an analgesic neurostimulation. Customized, their solution is adapted to each patient thanks to an instantaneous measurement andanalysis of the pain by facial, vocal and postural recognition. | $5.8M | Seed | Nov 18, 2020 |  |

4 of 4 investments shown.

## Co-investors
- [Better Angle](https://shizune.co/investors/profile/better-angle) — VC Fund, 2 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 2 deals together
- [AQUITI Gestion](https://shizune.co/investors/profile/aquiti-gestion-aci) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [Epopée Gestion](https://shizune.co/investors/profile/epop%C3%A9e-gestion) — VC Fund, 1 deal together
- [Good Only Ventures](https://shizune.co/investors/profile/good-only-ventures) — VC Fund, 1 deal together

## About KREAXI

VC Fund · Limonest, France

Kreaxi is a management company specializing for over 30 years in investing in the capital of innovative and technological startups with high potential.

5 contacts available at KREAXI.

| Name | Title | Profile |
| --- | --- | --- |
| Isabelle BOU-ANTOUN | Managing Director | https://shizune.co/investors/profile/isabelle-bou-antoun |
| Sophie Pierrin-Lepinard | Managing Director | https://shizune.co/investors/profile/sophie-pierrin-lepinard |
| Anne-Lise Flandin | Assistant de gestion | https://shizune.co/investors/profile/anne-lise-flandin |
| Fabrice Lacroix | Investment Committee Member | https://shizune.co/investors/profile/fabrice-lacroix |
| Flora Loger | Head of Legal and Internal Control | https://shizune.co/investors/profile/flora-loger |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Sophie Pierrin-Lepinard invest in?

Sophie Pierrin-Lepinard invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Sophie Pierrin-Lepinard last invest?

The most recent investment recorded for Sophie Pierrin-Lepinard closed in Jun 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co